MedTrace Logo

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

NCT04119336 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2023-08-21

Study results available
· View outcomes & findings →

Summary

This research is being done to assess the effectiveness and safety of the combination of nivolumab with ixazomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.

Conditions

  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma

Interventions

DRUG

Nivolumab

Given intravenously once per cycle

DRUG

Ixazomib

Given orally on days 1, 8, 15.

DRUG

Dexamethasone

Given orally on days 1, 8, 15, 22

DRUG

Cyclophosphamide

Given intravenously on days 1, 8, 15.

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Takeda Pharmaceuticals North America, Inc.

    collaborator INDUSTRY

  • Andrew Yee, MD

    lead OTHER

Principal Investigators

  • Andrew Yee, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-14
Primary Completion
2020-11-12
Completion
2022-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04119336 on ClinicalTrials.gov